| abstract |
598074 The disclosure relates to a novel hydroxyphenyl compound, 4-(4-ethyl-5-fluoro-2-hydroxyphenoxy)-3-fluorobenzamide, to the preparation of the compound and intermediates used therein, to the use of the compound as an antibacterial medicament and pharmaceutical compositions containing the compound. Infections which may be treated with the disclosed compound includes infections caused by the organisms methicillin-susceptible Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin resistant Staphylococcus aureus (VRSA) strains, Acinetobacter baumannii, Bacillus anthracis, Chlamydophila pneumoniae, Escherichia coli, Haemophilus influenzae, Helicobacter pylori, Klebsiella pneumoniae, Neisseria meningitidis, S. intermedius, P. multocida, B. bronchiseptica, M. haemolytica and A. pleuropneumoniae, and also bacteria such as Mycobacterium tuberculosis or other organisms such as Plasmodium falciparum. |